Advertisement
Advertisement

NTLA

NTLA logo

Intellia Therapeutics, Inc

17.43
USD
Sponsored
-0.41
-2.30%
Jul 07, 16:00 UTC -4
Closed
exchange

After-Market

17.21

-0.22
-1.25%

NTLA Earnings Reports

Positive Surprise Ratio

NTLA beat 23 of 41 last estimates.

56%

Next Report

Date of Next Report
Jul 30, 2026
Estimate for Q2 26 (Revenue/ EPS)
$14.27M
/
-$0.82
Implied change from Q1 26 (Revenue/ EPS)
-5.15%
/
+1.23%
Implied change from Q2 25 (Revenue/ EPS)
+0.19%
/
-16.33%

Intellia Therapeutics, Inc earnings per share and revenue

On May 11, 2026, NTLA reported earnings of -0.81 USD per share (EPS) for Q1 26, beating the estimate of -0.93 USD, resulting in a 13.10% surprise. Revenue reached 15.05 million, compared to an expected 15.09 million, with a -0.27% difference. The market reacted with a +2.34% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -0.82 USD, with revenue projected to reach 14.27 million USD, implying an increase of 1.23% EPS, and decrease of -5.15% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Replimune Group, Inc.
Report Date
Jun 29, 2026 For Q4 26
Estimate
-$0.72
Actual
-$0.76
Surprise
-4.52%
logo
Beyond Air, Inc. Common Stock
Report Date
Jun 26, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.63
Surprise
-9.00%
FAQ
For Q1 2026, Intellia Therapeutics, Inc reported EPS of -$0.81, beating estimates by 13.1%, and revenue of $15.05M, -0.27% below expectations.
The stock price moved up 2.34%, changed from $14.09 before the earnings release to $14.42 the day after.
The next earning report is scheduled for Jul 30, 2026.
Based on 13 analysts, Intellia Therapeutics, Inc is expected to report EPS of -$0.82 and revenue of $14.27M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement